Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Diazoxide choline controlled release - Soleno Therapeutics

Next Previous
Drug Profile

Diazoxide choline controlled release - Soleno Therapeutics

Alternative Names: C601; C602; DCCR; DCCR - Soleno Therapeutics; Diazoxide choline; Diazoxide choline controlled release; Diazoxide-choline-controlled-release-Essentialis; VYKAT XR

Latest Information Update: 08 Jan 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Essentialis
  • Developer Essentialis; Soleno Therapeutics
  • Class Antihyperlipidaemics; Antihypertensives; Antihypoglycaemics; Benzothiadiazines; Chlorobenzenes; Ethanolamines; Obesity therapies; Peripheral vasodilators; Small molecules; Sulfonamides
  • Mechanism of Action Potassium channel agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Prader-Willi syndrome; Glycogen storage disease type I
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed Prader-Willi syndrome
  • Phase II Hypertriglyceridaemia
  • Discontinued Hypoglycaemia; Obesity

Most Recent Events

  • 05 Jan 2026 Updated efficacy data from an open-label extension phase III trial in Prader-Willi syndrome released by Soleno Therapeutics
  • 22 May 2025 Preregistration for Prader-Willi syndrome (In children, In the elderly, In adolescents, In adults) in European Union (PO)
  • 22 May 2025 European Medicines Agency (EMA) validates marketing authorization application for diazoxide choline controlled release for Prader-Willi syndrome in the European union

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top